Hims Compounded GLP-1 Wind-Down: Timeline + Patient Options (May 2026)

On March 9, 2026, Hims & Hers and Novo Nordisk settled the patent-infringement lawsuit that Novo had filed three weeks earlier. Under the settlement terms reported by HMP Global, Hims agreed to stop advertising compounded GLP-1 products. New patients are now routed to FDA-approved Wegovy and Ozempic at Novo’s self-pay prices. Existing compounded patients are being transitioned, with full discontinuation expected by mid-2026.

This is what that means in practice, when it happened, and what paths exist for patients affected by the change.

What Hims announced — and when

The wind-down did not happen in a single announcement. It is the end-point of a sequence:

The Novo Nordisk settlement, March 9, 2026

On February 9, 2026 Novo filed a patent-infringement suit in the District of Delaware against Hims and fourteen other compounders, asserting US Patent No. 8,129,343 (semaglutide compound, expiring December 2031) per CNBC coverage. Twenty-eight days later the Hims piece settled. Novo dismissed the suit against Hims while reserving the right to refile if Hims breaches the agreement. The settlement preserved one limited carve-out: Hims may still provide compounded GLP-1s where a provider specifically documents clinical necessity for an individual patient. The fourteen other defendants remain in active litigation.

The February 2026 oral-pill episode

On February 5, 2026 Hims announced a compounded semaglutide pill at $49/month — a move that triggered immediate drops in both Novo Nordisk’s and Eli Lilly’s share prices and prompted Novo to announce it would take legal action. Within approximately four days the company withdrew the product under FDA pressure and Novo’s imminent lawsuit per BioPharma Dive. The pill never reached steady-state sale; it is not the same product as the current FDA-approved oral Wegovy.

On Reddit, the launch drew sharp scepticism. The top comment on a r/Semaglutide thread tracking the episode stated: “Will be a scam like all the other compounded oral GLP-1s” — pointing out that if a simpler delivery system than Novo’s SNAC co-formulation were effective, Novo would already be using it. That post accumulated 59 upvotes within days. Others were more pragmatic: one commenter with 88 upvotes noted that “the prices of GLP-1s have very little to do with the cost to make them,” framing the $49 pill as a pricing story rather than a scientific one.

The FDA warning letters, September 2025

On September 9, 2025 FDA issued warning letters to both Hims (716567) and Hers (716825), citing misleading marketing of compounded semaglutide as containing “the same active ingredient as Ozempic and Wegovy” and failure to submit required adverse-event reports.

The Novo partnership termination, June 2025

In April 2025, Novo and Hims announced a deal to sell brand-name Wegovy at $599/month through Hims’s platform. On June 23, 2025, Novo terminated the partnership in a public press release citing “illegal mass compounding and deceptive marketing.” Hims’s share price fell roughly 30% on the day.

The wind-down schedule — what stops and what continues

Note on pricing: Hims pricing changed as the platform transitioned from compounded to branded products. The prices above reflect Hims’s published self-pay rates as of mid-2026 per current platform guidance. They do not include any Hims platform or membership fee; verify your total all-in cost with Hims directly before enrolling.

The real cost of the transition — what patients are experiencing

The financial anxiety around the Hims transition is real and consistent across patient forums. One user in r/Ozempic summarised the situation faced by many compounded patients mid-transition: “I’m in the US and prices are ridiculous here” — commenting on a thread about crossing to Canada for lower-cost generics as an alternative when US compounded access ended. In r/Semaglutide, a May 2026 poster who had lost 90 pounds using compounded tirzepatide via telehealth over 15 months specifically attributed their success to cost access: “the cost is so significantly less that I wouldn’t have been able to afford the name brand, and my insurance doesn’t cover it, especially because I am not diabetic.” That post drew 101 upvotes.

One long-time Hims user who had started on “generic GLP-1 provided by Hims” in January 2025 and lost 35 pounds over eight months wrote about the experience in September 2025 — before the final settlement — framing the medication purely in terms of the scientific outcome: “The food noise telling me to eat the whole bag of Doritos or a 6-pack of IPAs is gone.” He did not address the regulatory uncertainty. That kind of patient account — clinical success obtained through a pathway that has since been closed — is the subtext of most of the transition anxiety circulating in patient communities in 2026. The drug worked; the question is whether patients can afford it at brand prices.

The Q1 2026 earnings results from Hims, released May 12, 2026, showed the financial strain the transition is imposing on the platform itself: Hims shares fell roughly 13% on weak guidance, with analysts pointing to GLP-1 brand-transition costs squeezing margins as the compounded pipeline ended. The transition is expensive for the platform as well as the patients.

If you are an existing Hims compounded patient

What your account looks like today

Hims is not publishing a day-by-day transition calendar publicly. The settlement requires Hims to stop advertising compounded products and to complete the exit by mid-2026; the transition of existing patients is managed in-app and via account communications. If you have an active subscription, check your Hims account for a communication about your next refill and what it will contain.

What happens at your next renewal

Per the settlement terms, Hims has agreed to move advertising away from compounded GLP-1s. What happens to your specific refill depends on where you are in the transition. In limited cases where a prescriber documents clinical necessity, compounded product may still be dispensed; otherwise the default is a branded product at Novo’s self-pay rates. The only source for your individual account status is Hims directly.

How to extract your prescription record before transition

Under HIPAA, you have the right to a copy of your medical records, including the prescription and any clinical notes. In most cases you can request these directly through your Hims account portal or by emailing Hims’s patient-support team. Keep a copy regardless of which path you continue on; the prescription may be transferable to another provider.

The clinical-difference question

The §503A(b)(1)(D) personalised-dose pathway — the framing Hims used before the settlement — remains legally contested but is not closed by statute. For a precise explanation of what 503A pharmacies can and cannot do in 2026, see our 503A vs 503B pharmacy guide. If you have a documented clinical reason (an allergy to an inactive ingredient, a non-standard dose that your prescriber has documented as clinically necessary) the compounding pathway may still apply. Hims, however, is now bound by the settlement not to advertise this route. If you believe you have a genuine clinical basis, that conversation is between you and your prescriber.

The Hims branded path today

Wegovy injectable

Hims is selling injectable Wegovy through Novo’s NovoCare channel per the March 2026 announcement. The published Hims self-pay price as of mid-2026 is $299/month. NovoCare direct is $349/month flat ($199/month introductory for the two lowest doses) with no platform fee. The NovoCare direct price has not changed; the Hims price reflects their post-transition published rate.

Wegovy oral pill

This is FDA-approved semaglutide 1.5 mg and 4 mg for weight management, not the compounded pill Hims briefly offered in February 2026. The published Hims self-pay rate as of mid-2026 is $249/month. This is the same SNAC-co-formulated Wegovy oral that Novo sells; the price difference between Hims and NovoCare direct reflects platform positioning.

With commercial insurance plus the Novo Nordisk copay card, branded Wegovy through Hims or any channel can potentially cost $0–$25/month for eligible patients.

How Hims branded compares to NovoCare direct

If cost is your primary consideration, the medication itself is the same product whether you access it through Hims or NovoCare directly. The variable is the platform fee. Confirm with both Hims and NovoCare what your specific all-in monthly total will be before committing. Our NovoCare enrollment walkthrough covers the NovoCare-direct path.

Alternatives if you prefer not to stay with Hims

NovoCare direct — Wegovy injectable

Novo Nordisk’s own direct-to-patient program. No platform fee on top of the medication. The enrollment walkthrough is at our NovoCare page. $349/month flat; $199/month introductory for the two lowest doses.

LillyDirect for Zepbound — $299–$449/month

Eli Lilly’s direct-to-patient program for Zepbound (tirzepatide). Vials and pens now at the same cash-pay tier: $299/month for the 2.5 mg starter, $399/month for 5 mg, and $449/month for the 7.5 mg and above doses. No platform fee. The enrollment walkthrough is at our LillyDirect page.

Other telehealth providers still operating compounded programs

Several telehealth providers continue to operate compounded GLP-1 programs under the §503A(b)(1)(D) personalised-dose framing. Their sourcing, pricing, and legal status vary and change rapidly. Our compounding tracker lists current operating status for each provider, updated monthly.

The HHS-DoJ referral question

In February 2026, HHS referred evidence related to Hims’s GLP-1 marketing practices to the Department of Justice for potential investigation. A referral is not a charge. The DoJ can investigate, decline to pursue, or pursue enforcement. As of May 2026, no charges or enforcement actions from the DoJ referral have been publicly announced. Hims continues to operate. This is one of the signals we track in our monthly updates.

What we are watching next

Three signals will determine whether this page needs a significant update before its next quarterly refresh:

1. Settlement breach. Novo reserved the right to refile the patent suit. Any public allegation that Hims is continuing to market compounded GLP-1 products would be material.
2. DoJ referral outcome. Either a public declination or the opening of formal proceedings would change the risk picture.
3. Hims pricing changes. The mid-2026 published prices ($299/month injectable, $249/month oral Wegovy) are the current baseline; any changes to these rates or to platform/membership fee structures are worth monitoring if you are budgeting.

The broader regulatory context — the compounding cliff, the 503A/503B landscape, and the fourteen other defendants in Novo’s February 2026 suit — is on the compounding cliff timeline. Current operating status for all providers is on the compounding tracker.

For an independent editorial review of Hims's current product offering, see our Hims weight loss review.

If you spot an error or a missing source, email [email protected]. Our editorial policy and methodology explain our sourcing approach and how we disclose conflicts of interest.